Investors Sell Becton Dickinson and (BDX) on Strength After Insider Selling
Traders sold shares of Becton Dickinson and Co (NYSE:BDX) on strength during trading hours on Monday after an insider sold shares in the company. $105.46 million flowed into the stock on the tick-up and $190.09 million flowed out of the stock on the tick-down, for a money net flow of $84.63 million out of the stock. Of all equities tracked, Becton Dickinson and had the 0th highest net out-flow for the day. Becton Dickinson and traded up $1.75 for the day and closed at $218.89Specifically, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the sale, the director now directly owns 295,753 shares in the company, valued at approximately $64,420,918.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.
Several analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Piper Jaffray Companies restated an “overweight” rating and set a $260.00 price objective (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research report on Wednesday, January 3rd. Evercore ISI started coverage on shares of Becton Dickinson and in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective on the stock. Finally, Deutsche Bank set a $260.00 price objective on shares of Becton Dickinson and and gave the company a “buy” rating in a research report on Friday, December 29th. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $237.27.
The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. The firm has a market cap of $50,220.00, a PE ratio of 167.09, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is presently 229.01%.
A number of large investors have recently modified their holdings of BDX. Northern Trust Corp raised its position in Becton Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after purchasing an additional 106,966 shares during the period. Vanguard Group Inc. raised its position in Becton Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after purchasing an additional 1,353,780 shares during the period. Quantum Capital Management raised its position in Becton Dickinson and by 7.3% in the 2nd quarter. Quantum Capital Management now owns 1,499 shares of the medical instruments supplier’s stock worth $292,000 after purchasing an additional 102 shares during the period. ETRADE Capital Management LLC raised its position in Becton Dickinson and by 19.6% in the 2nd quarter. ETRADE Capital Management LLC now owns 14,889 shares of the medical instruments supplier’s stock worth $2,905,000 after purchasing an additional 2,437 shares during the period. Finally, TIAA FSB purchased a new position in Becton Dickinson and in the 2nd quarter worth $7,373,000. Institutional investors own 75.56% of the company’s stock.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.